Abstract
Although both pre- and postsynaptic mechanisms have been implicated in the analgesia produced by μ-opioids at the spinal cord, it is not known under what conditions these different controls come into play. Because the μ-opioid receptor (MOR) can be visualized in individual lamina II excitatory interneurons and internalizes into endosomes on ligand binding, we tested whether MOR internalization could be monitored and used to measure postsynaptic MOR signaling. To test whether endogenous opioids modulate these lamina II interneurons during noxious stimulation, we next assessed the magnitude of postsynaptic MOR internalization under a variety of nociceptive conditions.
As observed in other systems, we show that MOR internalization in dorsal horn interneurons is demonstrated readily in response to opioid ligands. The MOR internalization is dose-dependent, with a similar dose–response to that observed for opioid-induced increases in potassium conductance. We demonstrate that MOR internalization in lamina II neurons correlates precisely with the extent of analgesia produced by intrathecal DAMGO. These results suggest that MOR internalization provides a good marker of MOR signaling in the spinal cord and that postsynaptic MORs on lamina II interneurons likely participate in the analgesia that is produced by exogenous opioids. We found, however, that noxious stimuli, under normal or inflammatory conditions, did not induce MOR internalization. Thus, endogenous enkephalins and endomorphins, thought to be released during noxious peripheral stimuli, do not modulate nociceptive messages via postsynaptic MORs on lamina II interneurons. We suggest that any endogenous opioids that are released by noxious stimuli target presynaptic MORs or δ-opioid receptors.
Keywords: receptor internalization, spinal cord, nociception, analgesia, inflammation, substantia gelatinosa
Although the ability of spinally administered μ-opioids to produce analgesia is well documented, the mechanisms via which these opioids act are not understood fully. The μ-opioid receptor (MOR) is expressed by primary afferent nociceptors that terminate in lamina I and II of the dorsal horn and by glutamatergic interneurons in lamina II (Arvidsson et al., 1995a). Based on this distribution and on functional studies of opioid-induced activity, two major mechanisms for producing opioid analgesia have been proposed: presynaptic inhibition of neurotransmitter release from primary afferent nociceptors and postsynaptic hyperpolarization of excitatory interneurons. Unclear, however, are the conditions when these two mechanisms come into play.
Like other G-protein-coupled receptors, the MOR internalizes into endosomes in vitro and in vivo on exposure to receptor agonists (Arden et al., 1995; Sternini et al., 1996). Because receptor internalization is agonist-dependent, it has been suggested that internalization of seven-transmembrane-domain receptors can be used as a marker of their activity (Mantyh et al., 1995). For example, MOR internalization has been used to document opioid activity induced by estrogen priming and exogenous opioids in hypothalamus and enteric neurons, respectively (Sternini et al., 1996; Eckersell et al., 1998). Unfortunately, because of the small size and punctate appearance of synaptic terminals, light microscopic examination of MOR internalization cannot be used to monitor presynaptic MOR activity. By contrast, it should be possible to observe the internalization of the postsynaptic MOR in interneurons in lamina II where membrane and intracellular labeling are easily distinguishable. Although the relationship between opioid receptor internalization and function is not well established, we hypothesized that if MOR internalization correlates with MOR-mediated postsynaptic inhibitory effects, then MOR internalization could be used to monitor MOR signaling by these interneurons in vivo.
There is evidence that spinal cord MORs can be activated endogenously by pain-producing stimuli. For example, neurochemical studies demonstrated that endogenous enkephalins are released into spinal CSF after repeated noxious stimulation; these could target and activate spinal cord MORs (Le Bars et al., 1987; Bourgoin et al., 1988,1990; Cesselin et al., 1989). Furthermore, the newly discovered μ-opioid peptides, endomorphin-1 and endomorphin-2, are localized in the spinal cord dorsal horn, in the terminals of small diameter neuropeptide (substance P and calcitonin gene-related peptide) containing primary afferents (Martin-Schild et al., 1998; Pierce et al., 1998). Because many of the latter are nociceptors, they could provide a source of pain-induced endogenous opioid activity at postsynaptic MORs. To address this question in the present study, we examined the relationship between MOR internalization in lamina II interneurons and MOR-related signaling and behavior. Using MOR internalization as a marker of opioid-induced activity, we also addressed the question as to whether postsynaptic MOR signaling modulates spinal nociceptive processing under normal and inflammatory conditions.
MATERIALS AND METHODS
Internalization of lamina II MORs in vivo
To establish that MOR internalization occurs and can be observed in lamina II interneurons, we first examined the ability of various exogenously applied μ-opioid receptor agonists to internalize the MOR in the spinal cord. The following compounds and injection protocols were used.
Intrathecal injection. Rats were anesthetized with halothane; then DAMGO, morphine, or endomorphin-1 was injected in 20 μl of saline with a Hamilton syringe. A 27.5 gauge needle was inserted between the L4/L5 vertebrae above the cauda equina. Intrathecal placement was verified by a flick of the tail on needle entry.
Systemic injection. Morphine was injected subcutaneously at the nape of the neck. In some rats we injected remifentanil, a short-acting potent alkaloid μ-opioid agonist, into one hindpaw.
Morphine pellet implantation. We implanted 75 mg morphine pellets or equivalently sized vehicle pellets subcutaneously at the rear of the flank under halothane anesthesia. We implanted one pellet on day 1, two additional pellets on day 2, and another three pellets on day 3. These rats were perfused on day 4.
Perfusion and tissue preparation
After treatment the rats were anesthetized deeply with sodium pentobarbital (100 mg/kg) and then perfused intracardially with 50 ml of 0.1 m PBS, followed by 500 ml of 10% formalin. The brain and spinal cord were dissected out, post-fixed for 4 hr in the same fixative, and then transferred to a 30% sucrose solution. Sagittal sections (30 μm) of lumbar cord were cut on a freezing microtome.
Immunofluorescent labeling
Sections were blocked in 5% normal goat serum in 0.1m PBS with 0.3% Triton X-100 for 30 min and then incubated in a rabbit anti-MOR antibody (Incstar, Stillwater, MN) at a 1:5000 dilution overnight. Sections were washed and incubated in a Cy-3-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA) at a 1:600 dilution for 2 hr. Then the tissue was washed and mounted on gelatin-coated slides.
Time course of MOR recycling
To be certain that the stimulus-induced MOR internalization that occurred was indeed detectable, we first established the temporal parameters of internalization, namely, the length of time after ligand binding that MOR internalization could be observed. In these studies we injected 1.0 μg of DAMGO intrathecally and then assayed for analgesia 10 min after the injection by using the hot plate test. Only rats showing maximal analgesia (60 sec latency) were used for the study. This ensured that μ-opioid receptors were activated by the injection. Immediately after the testing the rats were injected with 1.0 mg/kg naloxone subcutaneously to prevent further activation of the μ-opioid receptor and thus mark the latest time at which μ-opioid receptor internalization could be induced. To confirm that naloxone had reversed the increase in latency, we again assayed analgesia on the hot plate 5 min after the naloxone injection. Then the rats were anesthetized with pentobarbital and perfused intracardially with 10% formalin at 7.5, 15, 30, 60, or 120 min after the naloxone injection. Tissue was processed for MOR immunoreactivity as above.
Hot plate test
Rats were placed in a Plexiglas container in which the floor was heated to 52.5°C. Behavior was monitored, and the latency until hindpaw licking was determined. Rats were removed from the hot plate as soon as a hindpaw was licked. The cutoff value was 60 sec.
Quantification of MOR internalization
For the in vivo studies we collected confocal images [Nikon 60× Plan apo (1.40 oil) objective, 2× zoom, 3.0 iris setting on a Bio-Rad MRC 1024 (Hercules, CA)] through the optical center of 20 MOR-LI lamina II neurons in the L4/L5 segments of each rat. The number of endosomes in each cell was counted from the images by an investigator who was unaware of the treatment that the rat had received. The average number of endosomes per neuron was calculated for each rat. Values are presented as mean ± SEM.
Correlation between MOR internalization and MOR-induced hyperpolarization
Although MOR internalization requires agonist binding, the relationship between MOR internalization and MOR-induced activity has not been demonstrated clearly. Because it is difficult to measure directly the opioid-induced internalization and hyperpolarization simultaneously, we mimicked the conditions that have been used to study opioid-induced hyperpolarization in interneurons of lamina II recorded in slice preparations of the dorsal horn (specifically the medullary dorsal horn; Grudt and Williams, 1994). We determined dose–response curves for MOR internalization by using both DAMGO and met-enkephalin, which were the agonists tested in the Grudt and Williams study. EC50 values were calculated with PRISM software (GraphPad Software, San Diego, CA). The curve was a sigmoidal dose–response.
Postnatal day (P) P15–P23 Sprague Dawley rats were anesthetized with halothane, and the lumbar and sacral spinal cord were dissected out. The spinal cord was placed in a bath of carbogenated sucrose buffer (in mm: 240 sucrose, 2.5 KCl, 1.3 MgSO4, 1.0 NaH2PO4, 10 glucose, 26 NaHCO3, and 2.5 CaCl2), and the dura, dorsal, and ventral roots were removed under a dissecting microscope. The cut surface of the lumbar cord was superglued to the stage of a Vibratome (Pelco 101 series 1000), placed against a 5% agar block, and immersed in carbogenated sucrose buffer. Transverse sections of spinal cord were cut at 500–600 μm and transferred to carbogenated incubation solution (in mm: 124 NaCl, 5 KCl, 1.3 MgSO4, 1.2 KH2PO4, 10 glucose, 26 NaHCO3, and 2.4 CaCl2) for 2 hr. After 2 hr the slices were transferred to a carbogenated recording solution at 37°C (in mm: 127 NaCl, 1.9 KCl, 1.3 MgSO4, 1.2 KH2PO4, 10 glucose, 26 NaHCO3, and 2.4 CaCl2) containing the designated concentration of opioid for 15 min. Then the slices were fixed overnight in 10% formalin and transferred to a 30% sucrose solution for several hours. Next they were cut at 40 μm on a freezing microtome. Immunohistochemistry and quantification of internalization were performed as for the in vivo studies except that confocal images were taken and quantified for only six MOR-LI lamina II neurons from each slice.
Correlation between MOR internalization and behavioral analgesia
We wished to test the hypothesis that the activation and internalization of MORs on lamina II interneurons are necessary for the analgesia produced by intrathecal μ-opioids. If this hypothesis is correct, then the extent of MOR internalization in lamina II at the lumbar segments innervated by the stimulated dermatome (in this case L4/L5 for the plantar surface of the hindpaw) should correlate with the magnitude of analgesia seen at the dermatome itself. To test this hypothesis, we examined this relationship in individual rats injected intrathecally with various doses of the μ-opioid agonist DAMGO.
Rats were tested on the hot plate test as described above. DAMGO was injected intrathecally in 20 μl of saline at doses of 0, 10, 100, or 1000 ng. Then 15 min after the injection the rats were tested again on the hot plate test to determine the extent of analgesia produced by the injection. At 25 min after injection the rats were anesthetized with pentobarbital and perfused for immunocytochemistry to visualize and quantify MOR internalization as described above.
Correlation coefficients and 95% confidence intervals (C.I.) were computed with Statview 4.02 (Abacus Concepts, Berkeley, CA). A Fisher's r to z transformation was used to test the statistical significance of the correlation.
Noxious stimuli
To determine whether noxious stimuli evoke the release of endogenous μ-opioid agonists that act on lamina II interneurons, we examined MOR internalization in lamina II interneurons throughout the lumbar and cervical spinal cord after exposure of the rat to various noxious stimuli. Stimuli were chosen to mimic those used in studies that detected enkephalin release in spinal CSF (Le Bars et al., 1987;Bourgoin et al., 1988, 1990; Cesselin et al., 1989) or that demonstrated the release of tachykinins from dense core vesicles of primary afferent C-fibers (Abbadie et al., 1997; Liu et al., 1997;Honoré et al., 1999; Trafton et al., 1999). Because endomorphins have been observed in small diameter primary afferents, we assume that these tachykinin-releasing stimuli would release these endogenous opioids also.
Rats were anesthetized with pentobarbital (50 mg/kg) and exposed to one of the following stimuli to the left hindpaw: 2 min pinch with a hemostat, 2 min immersion in a 52°C water bath, alternate immersion and removal from a 52°C water bath every 10 sec for 10 or 20 min, interplantar injection of capsaicin (100 μg in 20 μl), and interplantar injection of 50 μl of 5% formalin. Pinch and water bath stimuli also were assessed 2 d after injection of 100 μl of Freund's complete adjuvant (CFA) into the hindpaw, which produces a persistent inflammation. Rats were perfused 5–15 min after the end of the stimulation. We also evaluated the effect of intrathecal injection of NMDA (6.8 ng in 20 μl) and direct electrical stimulation of the sciatic nerve (10 Hz, 0.5 msec; 10 mA for 1 min). Additional time points were tested for the pinch stimulus, with normal rats being perfused at 30 min and CFA-treated rats being perfused at 30 min and at 1, 2, and 3 hr after stimulus.
RESULTS
Exogenous opioid-evoked MOR internalization
To establish that agonist-induced internalization of the MOR occurs in the spinal cord in vivo, we tested a variety of opioid receptor agonists in rats and localized the MOR in lamina II neurons in the spinal cord dorsal horn. We performed immunofluorescent labeling with an antibody against the C-terminal tail of the MOR and examined sagittal sections of lumbar spinal cord. We found that in untreated, saline-injected, or vehicle-pelleted rats MOR-LI was confined to the plasma membrane, with fewer than five MOR-LI-containing endosomes per lamina II neuron (Fig.1A). In rats that were injected intrathecally with the opioid peptides DAMGO (1.0 μg in 20 μl) or endomorphin-1 (25 μg in 20 μl) 25 min before perfusion, MOR-LI was depleted from the plasma membrane and was observed in numerous endosomes within the neuron (Fig. 1B). Intraplantar (i.e., systemic) injection of remifentanil (10 μg in 50 μl) produced a comparable pattern of internalization of MOR-LI (Fig.1C). On the other hand, when we administered morphine systemically (10 mg/kg, s.c.), intrathecally (30 μg in 20 μl), or subcutaneously via pellets, internalization of the MOR-LI was very limited and generally indistinguishable from control levels (Fig.1D).
Time course of MOR recycling
To ensure that MORs did not recycle before we could detect their internalization in response to a stimulus, we believed it was important to establish the time course of the internalization process, specifically how long the receptor remains internalized. To this end we determined the extent of MOR-LI internalization at various times after agonist application; this provided a rough time course of the receptor recycling process. Rats were injected intrathecally with DAMGO; 10 min were allowed for the drug to spread and activate MORs. At this time the rats were given a systemic injection of naloxone to displace DAMGO from the receptor and to prevent further action of any DAMGO that persisted in the CSF. Rats were perfused at various times after the naloxone injection, and the average number of endosomes per lamina II neuron was determined for 20 neurons of the L4 segment. We found that internalization of the MOR peaked at 15 min (Fig.2). By 60 min the MOR immunoreactivity was indistinguishable from that seen in untreated animals, suggesting that MOR had been recycled to the plasma membrane. Because some MOR internalization was still observed at 30 min, it appears that there is an approximate half-hour window after activation during which MOR internalization can be detected immunocytochemically.
Correlation between MOR internalization and MOR-induced hyperpolarization
Although the phenomenon of MOR internalization is well documented, the relationship between MOR internalization and opioid function is less clear. μ-Opioids hyperpolarize a subpopulation of lamina II interneurons in the dorsal horn in a dose-dependent manner. Thus, Grudt and Williams (1994) demonstrated that the μ-opioid agonists DAMGO and met-enkephalin induce potassium currents in substantia gelatinosa neurons; the EC50 for DAMGO-induced effects was 72 ± 12 nm (SEM). To determine the relationship between MOR internalization and this previously described postsynaptic inhibition of MOR-containing interneurons, we turned to a spinal slice preparation. We determined the dose–response relationship for DAMGO-induced MOR internalization in these cells, mimicking the conditions that were used in the Grudt and Williams study. We found that bath application of DAMGO resulted in a dose-dependent internalization of the MOR in these neurons (EC50, 90.96 nm; 95% C.I., 2.7–3058 nm) (Fig.3A,C1–C3). This dose–response relationship is similar to that published for inducing potassium currents in lamina II interneurons (Grudt and Williams, 1994). We also examined the dose–response relationship for met-enkephalin-induced MOR internalization. As previously described, fairly high concentrations of met-enkephalin were necessary to activate the MOR (Fig. 3B). Maximal MOR internalization occurred at a concentration of 50 μm. This is slightly higher than would be predicted on the basis of the single dose (3.0 μm) tested in the Grudt and Williams study. However, because peptidase inhibitors were used in the electrophysiological study, somewhat lower doses may have been effective.
Correlation between MOR internalization and opioid-induced behavioral analgesia
Although the dose–response curve for MOR internalization in lamina II interneurons is comparable with that producing hyperpolarization of a similar population of neurons, the relationship between MOR internalization and the behavioral effects of opioids has not been demonstrated. Thus, to determine whether the internalization of the MOR in lamina II of the spinal cord correlates with spinal opioid-induced analgesia, we compared the magnitude of MOR internalization in lamina II neurons with the magnitude of behavioral analgesia on the hot plate test after intrathecal injection of DAMGO. We found that the dose–response relationship for internalization of the MOR in lamina II of the lumbar spinal cord was remarkably similar to that which plotted analgesia in the hot plate test (Fig.4A). Furthermore, there was a high correlation between the magnitude of analgesia and the average number of endosomes per lamina II neuron of the lumbar spinal cord seen in individual rats [Fig. 4B; correlation coefficient, 0.913 (95% C.I., 0.807–0.962); p = <0.0001].
Noxious stimuli
Several studies have demonstrated that endogenous opioids are released in the spinal cord after noxious stimuli (Yaksh and Elde, 1981; Le Bars et al., 1987; Bourgoin et al., 1988, 1990). Here we examined whether noxious stimulation also induces MOR internalization in lamina II interneurons. In these studies we monitored MOR-LI in lamina II of lumbar spinal cord after noxious stimuli of various modalities. We chose stimulus paradigms that modeled those used in studies that demonstrated spinal cord release of enkephalins or primary afferent neuropeptides. In none of these experiments did we detect significant MOR internalization (Fig.5).
It is significant that each of these stimuli induced internalization of the NK-1 receptor in lamina I of the spinal cord in the same animals (data not shown; but see Liu et al., 1997; Abbadie et al., 1997;Honoré et al., 1999; Trafton et al., 1999). We are, therefore, confident that the stimuli were of sufficient intensity to release dense core vesicles from at least a subpopulation of small diameter primary afferents. Because nonsegmental enkephalin release has been reported (Le Bars et al., 1987), we also examined sagittal sections of both lumbar and cervical spinal cord. Regardless of the areas that were examined, we could not distinguish MOR localization in lamina II spinal cord neurons from animals that were treated as described (see Materials and Methods) from those in untreated animals.
Because there is evidence for enhanced release of opioids during peripheral inflammation, we also studied MOR internalization under these conditions. Again, none of the stimuli that were tested induced any detectable MOR internalization in the spinal cord (Fig.6). Among the stimuli that were used was intraplantar injection of 5% formalin, a stimulus that produces both inflammation and pain behavior. Noxious stimuli in the presence of fully developed inflammation were also ineffective. Furthermore, MOR internalization was not observed after the induction of profound inflammation of the hindpaw and ankle with CFA. Even superimposed on these inflammatory conditions, a noxious pinch of the hindpaw for 2 min (at 5, 30, 120, or 180 min) or immersion of the hindpaw in a 52°C water bath for 2 min (at 5 min) did not induce MOR internalization.
DISCUSSION
In the present study we show that MOR internalization occurs in the spinal cord in a manner comparable with that observed in the hypothalamus (Eckersell et al., 1998), in the enteric nervous system (Sternini et al., 1996) and in cultured cells (Arden et al., 1995;Keith et al., 1996). We could detect significant MOR internalization after the administration of opioids locally or systemically. However, as previously described (Keith et al., 1996), morphine did not induce comparable internalization of the MOR, even with long exposures or when high doses were used. Importantly, all endogenous opioids as well as most nonmorphine alkaloid agonists (such as remifentanil) tested in this and other studies (Burford et al., 1998; Keith et al., 1998;McConalogue et al., 1999) induced the internalization of MORs. Thus, although it is possible for an opioid to induce MOR signaling without internalization (specifically morphine), it is unlikely that endogenous MOR ligands would signal via the MOR without triggering visible internalization and recycling.
We found that the MOR is internalized rapidly and recycles to the plasma membrane within ∼60 min. This time course is similar to that observed for other G-protein-coupled receptors (Mantyh et al., 1995) and suggests that there is an ∼30 min time window in which receptor activation can be detected. Importantly, this relatively prolonged window of recycling time ensures that we did not miss any significant MOR internalization that might have occurred after the release of endogenous opioids. The animals were perfused long before the receptor would have recycled completely.
Of additional note, we found that the behavioral analgesia produced by intrathecal DAMGO injection is maintained for at least 30 min, yet it can be reversed fully by naloxone within minutes. Recycling of the MOR, however, is not completed for >30 min after naloxone treatment. The fact that naloxone can reverse the analgesia produced by DAMGO much more quickly than the receptors appear to recycle suggests that the prolongation of DAMGO analgesia requires ongoing interactions with and activation of the MOR. This result also indicates that the duration of the DAMGO analgesia is not the result of extended second messenger signaling or activation of a circuit triggered by an initial interaction with MORs. It follows from this conclusion that not all MORs on a given neuron are desensitized functionally during the period in which most of the immunoreactivity appears to be endosomal. Thus, despite the internalization of a large population of MORs, a significant number of nondesensitized receptors likely remain at the plasma membrane, even in the presence of high doses of a high efficacy agonist.
Relationship between MOR internalization and MOR signaling
The similarity between the dose–response curves obtained here for DAMGO- and enkephalin-induced MOR internalization and those previously described for MOR-activated potassium currents suggests that MOR internalization provides a useful and accurate functional marker of MOR-induced signaling. In fact, analysis of the dose–response curves obtained for MOR-induced hyperpolarization (Grudt and Williams, 1994) suggests that MOR internalization is as good a marker of MOR signaling as intracellular recordings and can indicate whether postsynaptic inhibition is occurring by the mechanisms that have been proposed. It is, of course, possible that some consequences of MOR activation occur that we cannot detect by monitoring internalization; however, this is probably below the threshold for inducing potassium conductance and thus should not affect the membrane potential of the neuron significantly. Using a slightly different quantification method (counting the percentage of neurons with MOR internalization rather than number of MOR-positive endosomes), Marvizon et al. (1999) recently reported a similar dose–response for DAMGO-induced MOR internalization in the spinal cord slice (EC50, 30 nm). As these authors pointed out, the EC50 values for MOR internalization in the spinal cord slice are nearly identical to those obtained for adenyl cyclase inhibition or [γ-35S]GTP binding in cell culture systems (Keith et al., 1996, 1998; Yabaluri and Medzihradsky, 1997). These data provide further evidence that MOR internalization can be used as a functional marker of MOR activation.
DAMGO-induced MOR internalization correlated exceptionally well with DAMGO-induced hot plate analgesia. Indeed, only when rats were rendered analgesic by intrathecal DAMGO did we observe MOR internalization. This result suggests that postsynaptic MOR-mediated hyperpolarization of excitatory interneurons does occur and likely is involved in the behavioral analgesia produced by exogenous opioids. Of course, primary afferent-derived MORs are nearby and thus probably also would be exposed to DAMGO that accessed this region of the cord. In fact, if the primary afferent opioid receptor terminals were critical for the induction of spinal analgesia, then MOR internalization in lamina II neurons might correlate with, but not be critical to, the behavioral analgesia. The presence of internalization would indicate merely that sufficient drug had reached the appropriate region of the spinal cord. Nevertheless, our data, as well as our previous study of opioid effects on noxious stimulus-evoked tachykinin signaling (Trafton et al., 1999), are consistent with the hypothesis that lamina II postsynaptic MORs are key mediators of the analgesia that is produced by spinal opioids.
The close correlations between G-protein-coupled receptor internalization and functional activity that are found here are not unprecedented. Keith et al. (1998) found similar dose–response relationships for DAMGO- and etorphine-induced MOR internalization and the inhibition of forskolin-stimulated cAMP accumulation in stably transfected HEK-293 cells. We also found a tight correlation between tachykinin-induced NK-1 receptor internalization and tachykinin-induced increases in intracellular calcium in cultured spinal cord neurons (Trafton et al., 1999). Additionally, it has been suggested that MOR internalization is linked to some aspects of its signaling, specifically the activation of MAP kinase (Polakiewicz et al., 1998;Ignatova et al., 1999), demonstrating that internalization and activity may be related functionally, not just correlated temporally.
Consequences of noxious stimulation
Several studies suggested that noxious stimulation evokes the release of endogenous opioids into the spinal CSF. Nevertheless, we found no indication that MORs on interneurons in lamina II are internalized/activated by noxious stimulation. If endomorphins are released from primary afferent fibers during noxious stimuli, it seems that their activity is concentrated and possibly restricted to MORs on primary afferent terminals. Because MORs have been observed on the terminals of small diameter fibers that contain endomorphins (Martin-Schild et al., 1998), it follows that these endomorphins could act at a primary afferent autoreceptor, which would restrict further the C-fiber input. Based on our inability to detect opioid receptor internalization, these endomorphins do not appear to have postsynaptic effects in lamina II, unless their target postsynaptic neurons express a MOR splice variant that is not recognized by the antisera that have been used in the present study (Pan et al., 1999).
Our results also suggest that the met-enkephalin release that has been detected after noxious stimulation (Le Bars et al., 1987; Bourgoin et al., 1988, 1990; Cesselin et al., 1989) does not evoke postsynaptic effects via the MOR. Because the δ-opioid receptor (DOR) is found in the superficial dorsal horn (Arvidsson et al., 1995b) and because enkephalins have a higher affinity for DOR (Corbett et al., 1993), one possibility is that locally released enkephalins primarily activate this opioid receptor subtype. In support of this hypothesis, Mizoguchi et al. (1997) have shown that intrathecal met-enkephalin-induced analgesia is blocked by the δ2-opioid receptor antagonist naltriben, but not by the MOR antagonist CTOP. Alternatively, it is possible that noxious stimulation does not release opioid peptides in sufficient quantity to activate any opioid receptors. This possibility is consistent with the lack of effect of the general opioid receptor antagonist naloxone on nociceptive behaviors in animals or pain sensation in humans, in a number of acute pain models (El-Sobky et al., 1976; Goldstein et al., 1976; Grevert and Goldstein, 1978; North, 1978; Stacher et al., 1988). Also, mice lacking the MOR have been shown to have normal behavioral responses to acute noxious thermal stimuli (Matthes et al., 1996), further suggesting that endogenous μ-opioids are not involved in normal acute nociceptive responses.
Several studies reported that opioids are more effective under inflammatory conditions (Neil et al., 1986; Millan et al., 1988), and there is evidence that levels of enkephalin in the dorsal horn increase with peripheral inflammation (Millan et al., 1986; Iadarola et al., 1988). These results raised the possibility that greater amounts of enkephalin may be released and/or activate opioid receptors under inflammatory conditions (however, see Pohl et al., 1997). In fact, we found no indication of basal or noxious stimulus-evoked MOR signaling in the presence of inflammation. Therefore, it appears that, even under these conditions of hypersensitivity, spinal postsynaptic MORs are not activated endogenously.
Given that we found a profound analgesia associated with MOR internalization in lamina II interneurons, we suggest that this significant MOR internalization does not and indeed should not occur during normal or injury-related nociceptive responses. Were MORs activated to such an extent in vivo, responses to noxious stimuli would be blocked effectively, preventing the withdrawal from and attendance to stimuli that potentially are damaging. This is clearly undesirable and potentially life-threatening, particularly if the inhibition were a constant response to noxious stimulation.
The question remains as to the conditions under which the activation of MORs on lamina II interneurons occurs in vivo. Although it clearly is associated with the analgesia produced by exogenous opioids, one presumes that these receptors have a physiological/natural function. Given the evidence for an endogenous opioid contribution to the modulation of nociceptive behaviors, a function in stress- or sex-induced analgesia is a reasonable consideration, particularly because inattention to pain in these conditions might be beneficial to survival or reproduction.
Footnotes
This research was supported by National Institute of Health Grants DA 08377, NS 21445, and NS 14627. J.T. was supported in part by a National Science Foundation predoctoral fellowship, an Achievement Award for College Scientist scholarship, and the Veterans Affairs Health Services Research and Development Service. C.A. was supported by Institut National de la Santé et de la Recherche Médicale, France and Institut UPSA de la douleur.
Correspondence should be addressed to Dr. Allan I. Basbaum, Departments of Anatomy and Physiology, University of California San Francisco, 513 Parnassus, Box 0452, San Francisco, CA 94143-0452. E-mail:aib@phy.ucsf.edu.
Dr. Trafton's present address: VA Health Services Research and Development Center for Health Care Evaluation, 795 Willow Road (152 MPD), Menlo Park, CA 94025.
Dr. Abbadie's present address: Laboratory of Molecular Neuropharmacology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
REFERENCES
- 1.Abbadie C, Trafton J, Liu H, Mantyh PW, Basbaum AI. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci. 1997;17:8049–8060. doi: 10.1523/JNEUROSCI.17-20-08049.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Arden JR, Segredo V, Wang Z, Lameh J, Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK-293 cells. J Neurochem. 1995;65:1636–1645. doi: 10.1046/j.1471-4159.1995.65041636.x. [DOI] [PubMed] [Google Scholar]
- 3.Arvidsson U, Riedl M, Chakrabarti S, Lee J, Nakano A, Dado R, Loh H, Law P, Wessendorf M, Elde R. Distribution and targeting of a μ-opioid receptor (MOR1) in brain and spinal cord. J Neurosci. 1995a;15:3328–3341. doi: 10.1523/JNEUROSCI.15-05-03328.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Arvidsson U, Dado RJ, Riedl M, Lee JH, Law PY, Loh HH, Elde R, Wessendorf MW. δ-Opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. J Neurosci. 1995b;15:1215–1235. doi: 10.1523/JNEUROSCI.15-02-01215.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bourgoin S, Le Bars D, Clot AM, Hamon M, Cesselin F. Spontaneous and evoked release of met-enkephalin-like material from the spinal cord of arthritic rats in vivo. Pain. 1988;32:107–114. doi: 10.1016/0304-3959(88)90029-2. [DOI] [PubMed] [Google Scholar]
- 6.Bourgoin S, Le Bars D, Clot AM, Hamon M, Cesselin F. Subcutaneous formalin induces a segmental release of met-enkephalin-like material from the rat spinal cord. Pain. 1990;41:323–329. doi: 10.1016/0304-3959(90)90009-3. [DOI] [PubMed] [Google Scholar]
- 7.Burford NT, Tolbert LM, Sadee W. Specific G-protein activation and μ-opioid receptor internalization caused by morphine, DAMGO, and endomorphin I. Eur J Pharmacol. 1998;342:123–126. doi: 10.1016/s0014-2999(97)01556-2. [DOI] [PubMed] [Google Scholar]
- 8.Cesselin F, Bourgoin S, Clot A, Hamon M, Le Bars D. Segmental release of met-enkephalin-like material from the spinal cord of rats, elicited by noxious thermal stimuli. Brain Res. 1989;484:71–77. doi: 10.1016/0006-8993(89)90349-1. [DOI] [PubMed] [Google Scholar]
- 9.Corbett AD, Paterson SJ, Kosterlitz HW. Selectivity of ligands for opioid receptors. In: Herz A, editor. Opioids I. Springer; Berlin: 1993. pp. 645–679. [Google Scholar]
- 10.Eckersell CB, Popper P, Micevych PE. Estrogen-induced alteration of μ-opioid receptor immunoreactivity in the medial preoptic nucleus and medial amygdala. J Neurosci. 1998;18:3967–3976. doi: 10.1523/JNEUROSCI.18-10-03967.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.El-Sobky A, Dostrovsky JO, Wall PD. Lack of effect of naloxone on pain perception in humans. Nature. 1976;263:783–784. doi: 10.1038/263783a0. [DOI] [PubMed] [Google Scholar]
- 12.Goldstein A, Pryor GT, Otis LS, Larsen F. On the role of endogenous opioid peptides: failure of naloxone to influence shock escape threshold in the rat. Life Sci. 1976;18:599–604. doi: 10.1016/0024-3205(76)90339-8. [DOI] [PubMed] [Google Scholar]
- 13.Grevert P, Goldstein A. Endorphins: naloxone fails to alter experimental pain or mood in humans. Science. 1978;199:1093–1095. doi: 10.1126/science.343250. [DOI] [PubMed] [Google Scholar]
- 14.Grudt T, Williams JT. μ-Opioid agonists inhibit spinal trigeminal substantia gelatinosa neurons in guinea pig and rat. J Neurosci. 1994;14:1646–1654. doi: 10.1523/JNEUROSCI.14-03-01646.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Honoré P, Menning P, Rogers S, Nichols M, Basbaum AI, Besson JM, Mantyh PW. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J Neurosci. 1999;19:7670–7678. doi: 10.1523/JNEUROSCI.19-17-07670.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Iadarola MJ, Douglass J, Civelli O, Naranjo JR. Differential activation of spinal cord dynorphin and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization. Brain Res. 1988;455:205–212. doi: 10.1016/0006-8993(88)90078-9. [DOI] [PubMed] [Google Scholar]
- 17.Ignatova EG, Belcheva MM, Bohn LM, Neuman MC, Coscia CJ. Requirement of receptor internalization for opioid stimulation of mitogen-activated protein kinase: biochemical and immunofluorescence confocal microscopic evidence. J Neurosci. 1999;19:56–63. doi: 10.1523/JNEUROSCI.19-01-00056.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Keith D, Murray S, Zaki P, Chu P, Lissin D, Kang L, Evans C, Von Zastrow M. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem. 1996;271:19021–19024. doi: 10.1074/jbc.271.32.19021. [DOI] [PubMed] [Google Scholar]
- 19.Keith D, Anton B, Murray S, Zaki P, Chu P, Lissin D, Monteileet-Agius G, Stewart P, Evans C, Von Zastrow M. μ-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol. 1998;53:377–384. [PubMed] [Google Scholar]
- 20.Le Bars D, Bourgoin S, Clot AM, Hamon M, Cesselin F. Noxious mechanical stimuli increase the release of met-enkephalin-like material heterosegmentally in the rat spinal cord. Brain Res. 1987;402:188–192. doi: 10.1016/0006-8993(87)91066-3. [DOI] [PubMed] [Google Scholar]
- 21.Liu H, Mantyh PW, Basbaum AI. NMDA receptor regulation of substance P release from primary afferent nociceptors. Nature. 1997;386:721–724. doi: 10.1038/386721a0. [DOI] [PubMed] [Google Scholar]
- 22.Mantyh PW, DeMaster E, Malhotra A, Ghilardi JR, Rogers SD, Mantyh CR, Liu H, Basbaum AI, Vigna SR, Maggio JE, Simone DA. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science. 1995;268:1629–1632. doi: 10.1126/science.7539937. [DOI] [PubMed] [Google Scholar]
- 23.Martin-Schild S, Gerall AA, Kastin AJ, Zadina JE. Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers. Peptides. 1998;19:1783–1789. doi: 10.1016/s0196-9781(98)00136-3. [DOI] [PubMed] [Google Scholar]
- 24.Marvizon JC, Grady EF, Waszak-McGee J, Mayer EA. Internalization of μ-opioid receptors in rat sinal cord slices. NeuroReport. 1999;10:2329–2334. doi: 10.1097/00001756-199908020-00020. [DOI] [PubMed] [Google Scholar]
- 25.Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Keiffer BL. Loss of morphine-induced analgesia, reward effect, and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature. 1996;383:819–823. doi: 10.1038/383819a0. [DOI] [PubMed] [Google Scholar]
- 26.McConalogue K, Grady EF, Minnis J, Balestra B, Tonini M, Brecha NC, Bunnett NW, Sternini C. Activation and internalization of the μ-opioid receptor by the newly discovered endogenous agonists, endomorphin-1 and endomorphin-2. Neuroscience. 1999;90:1051–1059. doi: 10.1016/s0306-4522(98)00514-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Millan MJ, Millan MH, Czlonkowski A, Hollt V, Pilcher CW, Herz A, Colpaert FC. A model of chronic pain in the rat: response of multiple opioid systems to adjuvant-induced arthritis. J Neurosci. 1986;6:899–906. doi: 10.1523/JNEUROSCI.06-04-00899.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Millan MJ, Czlonkowski A, Morris B, Stein C, Arendt, Huber A, Hollt V, Herz A. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain. 1988;35:299–312. doi: 10.1016/0304-3959(88)90140-6. [DOI] [PubMed] [Google Scholar]
- 29.Mizoguchi H, Narita M, Kampine JP, Tseng LF. [Met5]enkephalin and δ2-opioid receptors in the spinal cord are involved in the cold water swimming-induced antinociception in the mouse. Life Sci. 1997;61:PL81–PL86. doi: 10.1016/s0024-3205(97)00542-0. [DOI] [PubMed] [Google Scholar]
- 30.Neil A, Kayser V, Gacel G, Besson JM, Guilbaud G. Opioid receptor types and antinociceptive activity in chronic inflammation: both κ- and μ-opiate agonistic effects are enhanced in arthritic rats. Eur J Pharmacol. 1986;130:203–208. doi: 10.1016/0014-2999(86)90269-4. [DOI] [PubMed] [Google Scholar]
- 31.North MA. Naloxone reversal of morphine analgesia but failure to alter reactivity to pain in the formalin test. Life Sci. 1978;22:295–302. doi: 10.1016/0024-3205(78)90136-4. [DOI] [PubMed] [Google Scholar]
- 32.Pan YX, Xu J, Bolan E, Abbadie C, Chang A, Zuckerman A, Rossi G, Pasternak GW. Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Mol Pharmacol. 1999;56:396–403. doi: 10.1124/mol.56.2.396. [DOI] [PubMed] [Google Scholar]
- 33.Pierce TL, Grahek MD, Wessendorf MW. Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. NeuroReport. 1998;9:385–389. doi: 10.1097/00001756-199802160-00005. [DOI] [PubMed] [Google Scholar]
- 34.Pohl M, Ballet S, Collin E, Mauborgne A, Bourgoin S, Benoliel JJ, Hamon M, Cesselin F. Enkephalinergic and dynorphinergic neurons in the spinal cord and dorsal root ganglia of the polyarthritic rat: in vivo release and cDNA hybridization studies. Brain Res. 1997;749:18–28. doi: 10.1016/s0006-8993(96)01161-4. [DOI] [PubMed] [Google Scholar]
- 35.Polakiewicz RD, Schieferl SM, Dorner LF, Kansra V, Comb MJ. A mitogen-activated protein kinase pathway is required for μ-opioid receptor desensitization. J Biol Chem. 1998;273:12402–12406. doi: 10.1074/jbc.273.20.12402. [DOI] [PubMed] [Google Scholar]
- 36.Stacher G, Abatzi TA, Schulte F, Schneider C, Stacher-Janotta G, Gaupmann G, Mittelbach G, Steinringer H. Naloxone does not alter the perception of pain induced by electrical and thermal stimulation of the skin in healthy humans. Pain. 1988;34:271–276. doi: 10.1016/0304-3959(88)90122-4. [DOI] [PubMed] [Google Scholar]
- 37.Sternini C, Spann M, Anton B, Keith D, Bunnett N, Von Zastrow M, Evans C, Brecha N. Agonist-selective endocytosis of μ-opioid receptor by neurons in vivo. Proc Natl Acad Sci USA. 1996;93:9241–9246. doi: 10.1073/pnas.93.17.9241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Trafton JA, Abbadie C, Marchand S, Mantyh PW, Basbaum AI. Spinal opioid analgesia: how critical is the regulation of substance P signaling? J Neurosci. 1999;19:9642–9653. doi: 10.1523/JNEUROSCI.19-21-09642.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Yabaluri N, Medzihradsky F. Down-regulation of μ-opioid receptor by full, but not partial, agonists is independent of G-protein coupling. Mol Pharmacol. 1997;52:896–902. doi: 10.1124/mol.52.5.896. [DOI] [PubMed] [Google Scholar]
- 40.Yaksh TL, Elde RP. Factors governing release of methionine enkephalin-like immunoreactivity from mesencephalon and spinal cord of the cat in vivo. J Neurophysiol. 1981;46:1056–1075. doi: 10.1152/jn.1981.46.5.1056. [DOI] [PubMed] [Google Scholar]